Dragozepic 5 mg

DRAGON PHARMA DRAGOZEPIC

Dragozepic 5 mg by Dragon Pharma is a high-purity GLP-1 receptor agonist peptide, extensively studied for its role in metabolic regulation and glucose control. This advanced peptide formulation is designed for scientific research and laboratory studies, providing precise and stable results in controlled environments.

DRUG COMPOSITION

Dragozepic is composed of a synthetic GLP-1 receptor agonist, developed to mimic the natural incretin hormone responsible for regulating insulin and glucose metabolism.

LAB TEST REPORT

PHARMACEUTICAL FORM

Dragozepic is provided as a lyophilized powder for reconstitution, ensuring optimal stability and controlled application. It is typically available as a 2 mL vial containing 5 mg of peptide.

PHARMACEUTICAL GROUP AND ATC CODE

Pharmaceutical group: Peptide-based GLP-1 receptor agonist
ATC code: A10BJ06

PHARMACOLOGICAL PROPERTIES

Dragozepic interacts with GLP-1 receptors, leading to the following research observations:

✔ Stimulates insulin release in response to glucose levels
✔ Suppresses glucagon secretion, aiding metabolic efficiency
✔ Slows gastric emptying, which may influence nutrient absorption
✔ Potential role in peptide-based metabolic research

PROFILE

• Chemical name: Dragozepic
• Chemical formula: C187H291N45O59
• Percentage of anabolic activity: Not applicable (not an anabolic steroid)
• Percentage of androgenic activity: Not applicable
• Active half life: Approximately 1 week
• Recommended dosage: Varies, typically once weekly
• Acne: Not a known side effect
• Bloating (water retention): Not a known side effect
• HBR: Not applicable
• Hepatic toxicity: Not a known side effect
• Aromatization: Not applicable

THERAPEUTICAL INDICATIONS

Dragozepic is being studied for metabolic research applications, including:

✔ GLP-1 receptor modulation
✔ Metabolic function and glucose homeostasis
✔ Peptide interactions in scientific studies

DOSES AND METHOD OF ADMINISTRATION

• Reconstitution: Using bacteriostatic water
• Administration: Research applications involve subcutaneous injection
• Frequency: Peptide stability allows for once-weekly research application

CYCLE/STACKING

Dragozepic is not cycled like performance-enhancing substances. It is typically used continuously in long-term metabolic studies.

POST CYCLE THERAPY

Post-cycle considerations are not applicable, as Dragozepic is a peptide for research purposes.

SIDE EFFECTS

Observations in controlled studies have reported:

✔ Mild nausea (temporary in early research phases)
✔ Gastrointestinal discomfort (low occurrence)
✔ Potential impact on metabolic markers

CONTRAINDICATIONS

Dragozepic should not be used in research subjects with:

⚠ Pre-existing gastrointestinal conditions
⚠ Hypersensitivity to GLP-1 receptor agonists
⚠ History of medullary thyroid carcinoma (MTC)

OVERDOSE

In research settings, excessive peptide exposure may result in:

🚨 Metabolic fluctuations
🚨 Hypoglycemic markers in controlled studies

WARNINGS AND SPECIAL PRECAUTIONS FOR USE:

⚠ Careful observation in peptide-based metabolic studies is recommended.
⚠ Potential influence on pancreatic function requires controlled monitoring.
⚠ Studies should adhere to ethical research standards and institutional guidelines.

INTERACTIONS WITH OTHER DRUGS

Research suggests that Dragozepic may interact with other peptide-based metabolic regulators, such as:

✔ Insulinotropic peptides
✔ GLP-1 co-agonists
✔ Metabolic function peptides

PRESENTATION, PACKAGING

• Form: Lyophilized powder
• Packaging: 2 mL vials (5 mg per vial)
• Storage: Refrigerate at 2°C to 8°C (36°F to 46°F)

STORAGE

Dragozepic should be stored according to the manufacturer's instructions, usually refrigerated, after reconstitution from powder.

DELIVERY TO THE USA

Dragozepic 5 mg by Dragon Pharma is available for secure and discreet shipping to the USA through trusted research peptide suppliers, such as Steroid.biz.

LEGAL STATUS

⚠ Dragozepic is a research peptide and is not intended for human consumption.
⚠ Legal status may vary by region – ensure compliance with local research regulations.

DATE OF LAST TEXT CHECKS

/

NAME AND ADDRESS OF THE MANUFACTURER

Dragon Pharma
Europe